Exscientia
AI for accelerated drug discovery
Oxford, United Kingdom
Exscientia is an AI-driven drug design and development company, founded in 2012, pioneering precision medicine to discover new therapies faster. It uses AI throughout the drug discovery cycle, including in silico design and automated robots, and was the first AI company to have designed a novel molecule for clinical trials.
How We Help
Problem Statement
Exscientia aims to disrupt traditional drug discovery pipelines, which are often characterized by high costs, long timelines, and high failure rates, by introducing an efficient, AI-driven approach.
Core Technology
generative artificial intelligence (AI) to discover new therapies
Key Differentiators
first AI company to have designed a novel molecule that entered clinical trials; accelerate drug design by up to 70%; decrease capital costs by 80%
Clinical Focus
Exscientia's internal pipeline is primarily focused on oncology. Through partnerships, its reach extends to immunology, neuroinflammation, inflammatory and auto-immune conditions, psychiatry, rare diseases, and the development of broad-spectrum antivirals.
Target Customers
Major pharmaceutical companies
Product Stage
Beta
Company Info
- Business Model
- Exscientia operates with a "full-stack" AI drug discovery model, developing its proprietary pipeline and forming collaborations with major pharmaceutical companies. It generates revenue through upfront payments, milestone payments, and potential royalties from these partnerships.
- Founded
- 2012
- Total Funding
- 510,000,000
- Website
- www.exscientia.ai
Categories
Disease Areas
Technologies
Clinical & IP
Clinical Validation
Aims to bring novel compounds to clinical entry in 12 to 18 months. Integrates human tissue testing for drug candidates.
MedStartr Index Score
?What do you think of Exscientia?
A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.